A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-10-10
DOI
10.1038/s41598-017-13530-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Versatile strategy for controlling the specificity and activity of engineered T cells
- (2016) Jennifer S. Y. Ma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
- (2016) Djoke Hendriks et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
- (2015) Valerie R Wiersma et al. mAbs
- Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
- (2015) José Medina-Echeverz et al. Cancer Immunology Research
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials
- (2014) Sufia Butt Hassan et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy
- (2014) Z. Zimmerman et al. INTERNATIONAL IMMUNOLOGY
- Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
- (2014) Kim L Brunekreeft et al. Molecular Cancer
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical targeting of the TNF and TNFR superfamilies
- (2013) Michael Croft et al. NATURE REVIEWS DRUG DISCOVERY
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
- (2011) M. de Bruyn et al. CLINICAL CANCER RESEARCH
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
- (2009) A. Wyzgol et al. JOURNAL OF IMMUNOLOGY
- Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
- (2008) E. Bremer et al. CANCER RESEARCH
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
- (2008) Edwin Bremer et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started